The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical Limited has announced a board meeting scheduled for March 20, 2025, to approve the annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder interests.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited operates in the biopharmaceutical industry, focusing on the development, manufacturing, and sales of a wide range of pharmaceutical products. The company is known for its innovative drug development and market presence in the healthcare sector.
YTD Price Performance: 4.82%
Average Trading Volume: 1,865
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.75B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.